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Introduction 
Leptomeningial carcimomatosis (LC) was 
first identified in the 1870 by Ebert in a pa-
tient with lung cancer, and was named in 
1902 by Sieffert as meningitis carcinomatosa 
(Schiff, Kesari & Wen, 2008). Sixteen thou-
sand patients globally will be diagnosed with 
LC each year (Abrey, 2002). There has been 
a significant rise in the incidence of LC since 
1970, thought to be due to improvements in 
the diagnostic techniques and neuro imaging 
available in today’s healthcare system 
(Schiff, Kesari & Wen, 2008). The rise in di-
agnosis is the direct result of patients surviv-
ing their primary cancer. Hence there is a 
need for health professionals to be aware of  
LC and the clinical presentation, in order to  
provide appropriate care and interventions 
along with the potential for future research 
and cure.  
Currently epidemiological studies suggest 
that 3-8% of patient with solid tumours will 
develop leptomeningeal metastasis (LM) 
throughout their illness (Abrey, 2002). Twen-
ty per cent of patients are diagnosed on au-
topsy. These are patients undiagnosed and 
asymptomatic (Le Rhun, Taillibert & Cham-
berlain, 2013).  It was determined that the 
rise in diagnosis is due to increased survival 
rates of cancer as a result of improved medi-
cal treatment. All cancers have the potential 
to metastasise into the meninges causing 
LM. The leading primary cancers associated 
with LM include lung cancer (10-26%), mela-
noma (5-25%), gastrointestinal (4-14%), can-
cer of unknown primary (1-7%) and breast 
cancer (12-35%)  (Le Rhun et al 2013). 
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The brain and spinal cord are surrounded by 
three membranes referred to as the menin-
ges, composed of the dura mater being the 
pachymeninges, arachnoid mater and pia 
mater referred to as the leptomeninges. The 
space between is referred to as the sub-
arachnoid space, containing the CSF and the 
Circle of Willis providing arterial blood supply. 
Approximately 140ml of cerebral spinal fluid 
surround the brain and spinal cord at any one 
time, replenishing approximately five times a 
day (Hickey, 2014). CSF is produced in the 
choroid plexus of the third, fourth and lateral 
ventricles. Tumours cells gain entry into the 
CSF and subarachnoid space by metastatic 
seeding. Entry is gained by hematogenous 
spread to the choroid plexus onto the lep-
tomeninges, primary hematogenous metasta-
sis through leptomeningeal vessels, metasta-
sis from the Batson venous plexus, retro-
grade dissemination, centripetal extension or 
direct extension from contiguous tumour de-
posits (Gleissner & Chamberlain, 2006; Le 
Rhun et al 2013). Once tumour cells have 
invaded the leptomeninges, the flow of CSF 
causes the seeding and infiltration of tumour 
cells in a diffuse and multifocal manner (Le 
Rhun et al 2013). Greatest infiltration occurs 
in the basal cisterns and dorsal surface of the 
spinal cord and cauda equina.  
Case Study 
Patient X presented to hospital with in-
creased confusion, ataxia and lower limb mild 
weakness. Histology included breast cancer 
where a left mastectomy and lymph node 
clearance was completed in the 14 months 
prior to diagnosis. Symptoms of leptomenin-
geal metastases are caused by pressure 
from the metastases placed on the nerves 
that run across the meninges in both the 
head and the spine. This includes those run-
ning from the spinal cord out to the body, and 
is dependent on the location of the metasta-
ses. Symptoms that occur simultaneously in 
both the head and the spine suggest a diag-
nosis of leptomeningeal metastases (LM). 
Leptomeningeal metastases can also cause 
hydrocephalus, a condition that occurs when 
the metastatic cancer interferes with the flow 
of cerebrospinal fluid around the brain. As the 
spinal fluid continues to be produced, an in-
crease in the intracranial pressure is then 
seen as the arachnoid villi are no longer able 
to effectively reabsorb the CSF. 
Clinical presentation occurs in a pleomorphic 
and multifocal manner with neurological signs 
and symptoms emerging over days to weeks. 
Symptoms correlate to the region of malig-
nant cell infiltration in the central nervous 
system (CNS). The clinical manifestation of 
LM can be caused by several different patho-
physiological mechanisms and can be char-
acterised into the following main categories: 
 cerebral hemisphere dysfunction caus-
ing a mass effect due to the invasion of
the leptomeninges and associated in-
flammation thus a raised intracranial
pressure (ICP) and occlusion of CSF
flow occurs.
 cranial nerve and spinal cord symp-
toms: Through direct involvement of
the tumour.
 exiting nerve roots (Demopoulos &
Brown, 2014; Drappatz & Batchelor,
2007; Hickey, 2014).
A recent study described the signs and 
symptoms of 150 patients with solid tumour 
LM (Clarke, Perez, Jacks, Panageas & 
DeAngelis, 2010; Clarke 2012; Demopoulos 
& Brown, 2014). Between 30-50% of patients 
describe headache as their initial symptoms 
(see Table 1). Headaches can be associated 
with raised ICP or meningeal irritation result-
ing in neck stiffness and pain, along with 
signs of nuchal rigidity. Headaches occurring 
due to a raised ICP are known to be associ-
ated with nausea, vomiting and dizziness. 
Table 1 (Above): Initial symptoms of LM as reported by patients. 
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These symptoms commonly occur in wave 
patterns caused by changes in position due 
to arachnoid villi failing to reabsorb CSF thus 
resulting in hydrocephalus. Altered mental 
status accounts for 11% of presenting symp-
toms with confusion, forgetfulness, disorien-
tation, lethargy or personality changes the 
most common. These changes in mental 
state are referred to as an encephalopathy, 
the result of hydrocephalus, seizure activity, 
cerebral dysfunction or a combination of 
those. When cranial nerves are directly in-
vaded by malignant cells within the subarach-
noid space, cranial neuropathy occurs.  
The first intervention in diagnosis is a lumbar 
puncture to obtain a CSF specimen. Malig-
nant cells are detected in 70-89% of CSF 
specimens (Le Rhun et al, 2013). Repeated 
samples are often necessary as only 50% of 
patients with LM on initial lumbar puncture 
exhibit positive cytology. Patients are 25% 
more likely to have positive cytology on se-
cond lumbar puncture. Multiple lumbar punc-
tures are often required due to the meningeal 
dissemination, where tumour cells are local-
ised in the brain rather than the spinal cord 
hence movement of CSF must occur in order 
to obtain a positive sample. Therefore nega-
tive CSF cytology is directly related to the 
flow of malignant cells within the spinal cord 
CSF when lumbar punctures are taken.  
Clinical finding on CSF analysis includes, an  
elevated opening pressure of > 200mm Hg in 
57% of patients,  decreased glucose concen-
tration, high protein concentration, lympho-
cytic pleocytosis and a positive cytology for 
malignant cells (Chamberlain, 2008; 
Drappatz & Batchelor, 2007; Palma, Fernan-
dez-Torron, Esteve-Belloch, Fontes-Villalba, 
Hernandez, Fernandez-Hidalgo, Gallego Pe-
rez-Larraya & Martinez-Vila, 2013). 
A positive MRI assessment of an undiag-
nosed patient includes a whole CNS scan 
where a complete neuraxis and A T1 C+ gad-
olinium enhancement is completed in order to 
obtain the primary diagnosis (Drappatz & 
Batchelor, 2007).  
Typical findings include a thin diffused en-
hancement along the contours of the gyri and 
sulci with multiple nodular deposits in the 
subarachnoid space in 30-50% of cases (Le 
Rhun et al, 2013). LM enhancement can be 
found in cerebellar folia, cortical surface, ba-
sal cisterns and ventral surface along the 
brainstem, indicating abnormal thickening 
and enhancement. However these are not 
the most common sites of LM.  Between 15-
25% of patients present with spinal enhance-
ment, showing linear or nodular enhance-
ment along the spinal cord or cauda equina 
where clumping of nerve roots can be seen 
(Le Rhun et al, 2013). CT is an uncommon 
practice due to poor diagnostic value, with 
significantly reduced sensitivities of 23-38% 
when compared with the MRI. 
Prognosis 
The overall prognosis for a patient with LM is 
poor; patients have an expected survival rate 
of 4-6 weeks if untreated and 4-6 months if 
treated. Research indicated that 14% of LM 
cases occur as a result of an advanced pri-
mary breast cancer with no well-established 
prognostic makers for patients with LM other 
than the presence of malignant cells within 
the CSF and low performance in Karnofsky 
performance status scale (Palma, et al 2013). 
Treatment 
Due to current poor prognostic outcomes, 
treatment aims to reduce mortality through 
improving and stabilising the patient’s neuro-
logical status, while maintaining neurological 
quality of life (Gleissner & Chamberlain, 
2006). Current treatment plans are com-
prised of intrathecal or systemic chemothera-
py and focal radiation therapy with the goal to 
reduce size of tumours and growth. Statisti-
cally 20% of patients who receive treatment 
will respond (Demopoulos & Brown, 2014; 
Palma et al, 2013). Suitable patients will un-
dergo insertion of a ventriculo-peritoneal 
shunt to alleviate hydrocephalus symptoms.  
Chemotherapy is the only treatment which 
allows for simultaneous treatment of the brain 
and spinal cord. Intrathecal administration is 
defined as injecting chemotherapy into a cer-
ebral- access device inserted surgically or via 
repeated lumbar punctures (Demopoulos & 
Brown, 2014). Intrathecal administration al-
lows for an even distribution throughout the 
subarachnoid space and is not required to 
cross the blood brain barrier (Drappatz & 
Batchelor, 2007). Access devices avoid the 
risk of epidural or subdural hematomas. 
Methotrexate and thiotepa are the most ef-
fective chemotherapies in the treatment of 
LM patients with metastasis from primary 
breast cancer (Demopoulos & Brown, 2014; 
Drappatz & Batchelor, 2007). Chemotherapy 
is administered initially twice weekly for three 
weeks then weekly for four week followed by 
monthly (Demopoulos & Brown 2014). 
Radiation therapy involves field radiotherapy 
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to symptomatic sites of the disease, bulky 
disease and sites where CSF flow is ob-
structed. The aim is to shrink tumour cells, 
stabilise neurological symptoms, establish 
CSF flow and relieve pain caused by radicu-
lopathies (Demopoulos, 2014).  
Nurses must consider the adverse effects of 
chemotherapy and radiation therapy. Admin-
istration of chemotherapy may result in raised 
ICP and impaired CSF flow. Nurses must 
observe for acute signs of fever, headache, 
nuchal rigidity, seizures, dizziness or blurred 
vision. Subacute signs include transverse 
myelitis, cranial nerve palsies, seizures or 
coma (Demopoulos, 2014). When administer-
ing radiation therapy the nurse should be 
aware of increased patient fatigue, changes 
in skin colour and flushing of skin along with 
skin tension and Lhermitte’s sign - an electri-
cal signal running from the back of the cervi-
cal spine to the tips of the feet, when the 
neck is bent forwards (Demopoulos, 2014). 
When selecting patient treatment options, 
chemotherapy or radiation therapy is consid-
ered and each play a significant role in the 
treatment of LM. Research indicates that in-
tra CSF chemotherapy is better on smaller 
LC tumours due to the thickness of cells and 
diffusion capacity (Demopoulos, 2014). Radi-
ation therapy is better at treating large bulky 
tumours and assisting in the restoration of 
CSF flow (Demopoulos, 2014). Combination 
therapy is currently the choice of treatment.  
Nurse’s Role 
When nursing a patient with LM the holistic 
approach is essential due to the array of 
symptoms a patient can display. Leg weak-
ness and difficulty walking are common 
symptoms, thus ongoing assessment of mo-
bility status including the need for walking 
aids, wheelchairs or hoisting devices. Refer-
ral to an occupational therapist before dis-
charge is also important. Regular speech and 
swallowing assessments should be per-
formed, as LM can increase the risk of aspi-
ration as cranial nerve deficits impair the abil-
ity to chew and swallow. Constipation is a 
significant issue for LM patients as de-
creased mobility, pain medications and 
chemotheraphy contribute to constipation 
(Drappatz & Batchelor, 2007). Nursing staff 
should commence a bowel regime including 
a high fibre diet, adequate oral intake and 
aperients. 
Conclusion    
As health professionals, it is important to note 
that in 3-8 % of patients with solid tumours, 
the chance of developing LM is a real consid-
eration. In Patient X’s case, due to a delayed 
diagnosis and intervention, prognosis and 
outcome was poor.  
MRI and lumbar puncture allows for earlier 
diagnosis and intervention, while chemother-
apy and radiation therapy improve longevity 
and quality of life.  Nurses are critical to the 
care of the LM patient. An understanding of 
the disease process and care required will 
ensure quality of life during the progression 
of the disease. With cancers increasing in 
today’s society and certain treatments readily 
available, health professionals will have an 
increased awareness of LM, therefore with 
the ability to  identify and treat earlier. 
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